HLB (028300) Fundamentals 2026 — Revenue Analysis | SniperIQ
HLB (028300) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩3.76T, trading at ₩28300.00 on the KOE. This SniperIQ fundamentals page covers HLB's valuation, profitability (net margin -228.0%), revenue (₩83.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is HLB's market cap?
HLB (028300) has a market capitalization of approximately ₩3.76T, trading at ₩28300.00 on the KOE. Market cap moves with the live share price.
What is HLB's P/E ratio?
HLB's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 9.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is HLB?
HLB runs a net profit margin of -228.0%, a gross margin of 32.9%, and an operating margin of -110.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does HLB generate?
HLB reported revenue of ₩83.9B for fiscal year 2025, with net income of -₩220.5B and earnings per share (EPS) of -1680.07. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does HLB pay a dividend?
HLB does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is HLB financially healthy?
HLB carries a debt-to-equity ratio of 0.65x and a current ratio of 0.28x, with a market beta of 0.42. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is HLB a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For HLB (028300) the key facts are: market cap ₩3.76T, revenue ₩83.9B, 52-week range 24150-69200. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track HLB's full fundamentals live
Get HLB's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.